FindTrial
Sign In

Immune profile of PIMS-TS

Role of neutralizing antibodies and inflammatory biomarkers in children with Paediatric Inflammatory Multisystem Syndrome - Temporally Associated with SARS-CoV-2 (PIMS-TS) - PIMS-TS Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030605
Enrollment
200
Registered
2021-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: nil: nil Intervention2: nil: nil Control Intervention1: analysis of neutralising antibodies, various cytokines, gene polymorphism and complement factor: analysis of neutralising antibod

Sponsors

NIHNIRTICER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Stored serum or plasma samples from a previous approved study at KKCTH

Exclusion criteria

Exclusion criteria: Caretakers and children who have not consented Children admitted to PICU for conditions other than PIMS-TS

Design outcomes

Secondary

MeasureTime frame
a. Correlation of neutralizing antibodies with disease manifestation. b. Correlation of various cytokines, chemokines, gene polymorphisms, complement proteins and other biomarkers with disease manifestation c. Proportion of children with stable levels of neutralizing Abs at months 3 and 12 Timepoint: 3 and 12 months—

Primary

MeasureTime frame
a. To identify the different immune phenotypes of PIMS-TS spectrum b. Better understanding of immunology of children with PIMS-TS c. One year serological follow up for PIMS-TS children Timepoint: 3, 6 and 12 months—

Countries

India

Contacts

Public ContactDr Aishwarya Venkataraman

National Institute for Research in Tuberculosis

draishwaryav@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026